---
title: "Berry Genomics plans to hold a controlling stake in YiYuan TongKang to provide integrated testing services for genetic diseases in newborns and children"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/252224665.md"
description: "Berry Genomics announced that its wholly-owned subsidiary, Berry Health, plans to establish a holding subsidiary, YiYuan TongKang, with Mr. Li Wei in Zhengzhou, with a registered capital of 1 million yuan, in which Berry Health will hold 60%. The company will collaborate with public medical institutions to provide genetic disease testing services for newborns and children, with the future registered capital expected to be no less than 50 million yuan"
datetime: "2025-08-08T11:47:08.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/252224665.md)
  - [en](https://longbridge.com/en/news/252224665.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/252224665.md)
generator: "portal-rs"
---

# Berry Genomics plans to hold a controlling stake in YiYuan TongKang to provide integrated testing services for genetic diseases in newborns and children

According to the Zhitong Finance APP, Berry Genomics (000710.SZ) announced that its wholly-owned subsidiary, Berry Health, intends to invest in establishing a holding subsidiary with individual Mr. Li Wei in Zhengzhou, Henan Province. The proposed registered name for the subsidiary is Henan Yiyuan Tongkang Gene Technology Co., Ltd. (referred to as "Yiyuan Tongkang"), with a registered capital of 1 million yuan. Among them, Berry Health will contribute 600,000 yuan with a shareholding ratio of 60%; individual Mr. Li Wei will contribute 400,000 yuan with a shareholding ratio of 40%. The joint venture plans to conduct integrated testing services for genetic diseases in newborns and children in key areas such as Henan through close cooperation with public medical institutions and clinical medical enterprises.

The registered capital will mainly be used for venue rent and initial personnel costs. The products and related services of the joint venture (including gene sequencing and AI intelligent services, etc.) will primarily be procured from Chengdu Berry Health Gene Technology Co., Ltd. and its subsidiaries.

It is worth mentioning that the joint venture will expand its operating funds through methods such as increasing registered capital based on business progress. If the future operating conditions of the joint venture meet the expectations of all parties, the registered capital is expected to be no less than 50 million yuan

### Related Stocks

- [000710.CN](https://longbridge.com/en/quote/000710.CN.md)

## Related News & Research

- [Bessent's bond gambit aimed at calming markets is instead stirring inflation worries](https://longbridge.com/en/news/296642975.md)
- [Trump’s Bond Buyback Push Puts Kevin Warsh in a Tough Spot — Peter Schiff Says Treasury ‘Pulled the Rug Out From Under’](https://longbridge.com/en/news/296615127.md)
- [Scott Bessent Brings His Hedge Fund Playbook To Treasury. The Bond Market Is Fighting Back](https://longbridge.com/en/news/296520391.md)
- [The rise in interest rates hit a 'raw nerve' at the White House. Bessent's plan has analysts on edge.](https://longbridge.com/en/news/296517751.md)
- [Germany's AfD eyes Saxony-Anhalt win as first step toward federal power](https://longbridge.com/en/news/296707147.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**